Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

Video

In Partnership With:

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms (MPNs).

In MPNs, if they are a transplant candidate, it is preferred to take them to transplant depending on the risk level, unless observation is appropriate, says Fleur-Lominy. Some patients can be observed because they are asymptomstic. However, when these patients start developing symptoms, transplant should not be delayed. Transplant should be the first option, and then a JAK inhibitor can be given later if the patient relapses or experiences disease progression, concludes Fleur-Lominy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,